JPRN-jRCT2021260021 Durvalumab Hepatitis B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2021260021—A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2021260021 is a hot trial to watch
Hepatitis B is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2021260021 is notable because it evaluates Durvalumab in a Phase 3 design while 無増悪生存期間 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2021260021 |
| Official title | A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Durvalumab, Calderasib |
| Sponsor | MSD KK (Tokyo) |
| Collaborators | Not reported |
| Geography | United Kingdom, Taiwan Province, Italy, Ukraine, Turkey, Greece, Netherlands, Germany, Poland, China, South Korea, Brazil, Argentina, France, Canada, United States, Australia, Japan, Spain |
| Enrollment | 27 |
| Primary endpoint | 無増悪生存期間 |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 27 participants across United Kingdom, Taiwan Province, Italy, Ukraine, Turkey, Greece, Netherlands, Germany, Poland, China, South Korea, Brazil, Argentina, France, Canada, United States, Australia, Japan, Spain shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: 無増悪生存期間
- Primary: Progression-free survival
- Secondary: ・全生存期間 ・安全性及び忍容性 ・客観的奏効及び奏効期間 ・無遠隔転移生存期間 ・全般的健康状態／QoL、身体機能及び役割機能
- Secondary: - Overall survival - Safety and tolerability - Objective response and duration of response - Distant metastasis-free survival - Global health status/QoL, Physical functioning and Role functioning
Benchmark readouts in the surrounding field
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
- A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
- A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Durvalumab (Approved; PDL1); Calderasib (Phase 3; KRAS G12C)
Company & Deal Intelligence context: MSD KK (Tokyo) — Japan — http://www.msd.co.jp
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
JPRN-jRCT2021260021 is a focused lens on Hepatitis B development. Its value will be determined by whether Durvalumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
